Metagenomi Therapeutics, Inc. (MGX)
0.6799
-0.05
(-6.96%)
USD |
NASDAQ |
Nov 06, 10:20
Metagenomi Therapeutics Enterprise Value : -55.34M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -55.34M |
| November 04, 2026 | -53.10M |
| November 03, 2026 | -54.23M |
| November 02, 2026 | -54.42M |
| October 30, 2026 | -53.47M |
| October 29, 2026 | -51.58M |
| October 28, 2026 | -51.90M |
| October 27, 2026 | -52.72M |
| October 26, 2026 | -53.95M |
| October 23, 2026 | -52.51M |
| October 22, 2026 | -52.11M |
| October 21, 2026 | -51.63M |
| October 20, 2026 | -51.54M |
| October 19, 2026 | -52.28M |
| October 16, 2026 | -53.33M |
| October 15, 2026 | -51.01M |
| October 14, 2026 | -50.41M |
| October 13, 2026 | -48.29M |
| October 12, 2026 | -44.41M |
| October 09, 2026 | -45.17M |
| October 08, 2026 | -45.42M |
| October 07, 2026 | -45.74M |
| October 06, 2026 | -44.03M |
| October 05, 2026 | -43.66M |
| October 02, 2026 | -44.41M |
| Date | Value |
|---|---|
| October 01, 2026 | -41.20M |
| September 30, 2026 | -42.90M |
| September 29, 2026 | -40.26M |
| September 28, 2026 | -39.88M |
| September 25, 2026 | -39.50M |
| September 24, 2026 | -39.50M |
| September 23, 2026 | -40.26M |
| September 22, 2026 | -39.88M |
| September 21, 2026 | -40.63M |
| September 18, 2026 | -41.39M |
| September 17, 2026 | -40.26M |
| September 16, 2026 | -39.50M |
| September 15, 2026 | -39.12M |
| September 14, 2026 | -37.99M |
| September 11, 2026 | -39.12M |
| September 10, 2026 | -39.12M |
| September 09, 2026 | -39.50M |
| September 08, 2026 | -39.12M |
| September 04, 2026 | -38.74M |
| September 03, 2026 | -39.12M |
| September 02, 2026 | -39.12M |
| September 01, 2026 | -38.74M |
| August 31, 2026 | -38.37M |
| August 28, 2026 | -37.99M |
| August 27, 2026 | -37.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.884B |
| Oncolytics Biotech, Inc. | 52.27M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.113B |
| Anixa Biosciences, Inc. | 89.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.48M |
| Revenue (Quarterly) | -0.257M |
| Total Expenses (Quarterly) | 27.22M |
| EPS Diluted (Quarterly) | -0.7298 |
| Earnings Yield | -366.0% |
| Normalized Earnings Yield | -365.97 |